Get startedLog in
    Picture of Nurexone Biologic logo

    NRX — Nurexone Biologic News Story

    0.000.00%
    ca flag iconLast trade - 00:00
    HealthcareSpeculativeMicro CapMomentum Trap
    All News

    Biotechnology firm NurExone's Q3 net loss widens

    Picture of Nurexone Biologic logoNurexone Biologic
    28/11/2025 14:26
    Overview

NurExone reports Q3 2025 net loss of $1.47 mln, an increase from Q3 2024

Company raised C$3.2 mln from warrant exercises to support working capital

New U.S. and Israel patents granted for exosome production process

Outlook

Company did not provide specific financial guidance

Result Drivers

WARRANT EXERCISE - Co raised C$3.2 mln from accelerated warrant exercises to support working capital

R&D EXPENSES: Net R&D expenses were $0.70 million in Q3 2025, compared to $0.50 million in Q3 2024

Key Details


    MetricBeat/MissActualConsensus Estimate
    Q3 Net Income-$1.47 mln
    

Analyst Coverage

Wall Street's median 12-month price target for Nurexone Biologic Inc is C$3.06, about 76.8% above its November 27 closing price of C$0.71

Press Release: ID:nGNX3RRFC4

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

    Recent news on Nurexone Biologic

    See all news